Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C36H37F2NO5 |
| Molecular Weight | 601.6795 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(CCCC(O)=O)C2=C(N1CCCC(O)=O)C(=CC=C2F)C#CC3=CC=C(OCCCCC4=CC=CC(F)=C4C)C=C3
InChI
InChIKey=SILHYVDKGHXGBL-UHFFFAOYSA-N
InChI=1S/C36H37F2NO5/c1-24-27(9-5-11-31(24)37)8-3-4-23-44-29-19-15-26(16-20-29)14-17-28-18-21-32(38)35-30(10-6-12-33(40)41)25(2)39(36(28)35)22-7-13-34(42)43/h5,9,11,15-16,18-21H,3-4,6-8,10,12-13,22-23H2,1-2H3,(H,40,41)(H,42,43)
Gemilukast (ONO-6950) is an orally active compound that has been evaluated for the treatment of asthma. It is an CysLT1 and CysLT2 antagonist. Activation of CysLT2 receptors has been suggested to contribute to antigen-induced bronchoconstriction (constriction of the airways in the lungs) in certain asthma patients. In addition to its CysLT1 and CysLT2 antagonist activity, Gemilukast was shown to dose-dependently reduce LTC4-induced bronchoconstriction in asthmatic models, and reduce antigen-induced constriction of isolated human bronchi. A phase II trial with Gemilukast was discontinued in 2018.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma. | 2015 Aug 13 |
|
| Expression of CysLT2 receptors in asthma lung, and their possible role in bronchoconstriction. | 2015 Oct |
|
| Effects of ONO-6950, a novel dual cysteinyl leukotriene 1 and 2 receptors antagonist, in a guinea pig model of asthma. | 2015 Oct 15 |
|
| A dual CysLT(1/2) antagonist attenuates allergen-induced airway responses in subjects with mild allergic asthma. | 2016 Dec |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
42I6GGX6D6
Created by
admin on Sat Dec 16 02:09:06 GMT 2023 , Edited by admin on Sat Dec 16 02:09:06 GMT 2023
|
PRIMARY | |||
|
9860
Created by
admin on Sat Dec 16 02:09:06 GMT 2023 , Edited by admin on Sat Dec 16 02:09:06 GMT 2023
|
PRIMARY | |||
|
46830962
Created by
admin on Sat Dec 16 02:09:06 GMT 2023 , Edited by admin on Sat Dec 16 02:09:06 GMT 2023
|
PRIMARY | |||
|
C166714
Created by
admin on Sat Dec 16 02:09:06 GMT 2023 , Edited by admin on Sat Dec 16 02:09:06 GMT 2023
|
PRIMARY | |||
|
300000037007
Created by
admin on Sat Dec 16 02:09:06 GMT 2023 , Edited by admin on Sat Dec 16 02:09:06 GMT 2023
|
PRIMARY | |||
|
1232861-58-3
Created by
admin on Sat Dec 16 02:09:06 GMT 2023 , Edited by admin on Sat Dec 16 02:09:06 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
